Intrauterine trauma remains one of the most challenging clinical dilemmas in modern reproductive medicine. When endometrial basalis layers sustain physical injury during curettage or operative hysteroscopy, a devastating cascade of oxidative stress and persistent inflammation begins. This pathological cascade frequently results in extensive endometrial fibrosis, leading to Asherman syndrome, secondary amenorrhea, and severe subfertility. Clinicians continuously search for transformative biomaterial technologies that can reliably prevent intrauterine adhesions while actively restoring functional endometrial receptivity. Recently, engineered multifunctional biomaterials have emerged as a revolutionary therapeutic paradigm, moving beyond passive barrier membranes to active microenvironmental reprogramming.

Pathophysiological Complexities in Intrauterine Adhesion Formation

Intrauterine adhesions develop through a self-reinforcing trifecta involving severe tissue hypoxia, chronic inflammation, and robust myofibroblast activation. Following physical or infectious endometrial disruption, damaged tissue produces excessive reactive oxygen species. Consequently, this local oxidative storm overwhelms endogenous antioxidant defenses, causing mitochondrial membrane depolarization and profound cellular dysfunction. In response, resident immune cells adopt a persistent pro-inflammatory M1 phenotype, releasing transforming growth factor-beta 1 (TGF-β1) and pro-fibrotic cytokines. Therefore, endometrial stromal cells undergo aberrant myofibroblast transdifferentiation, characterized by alpha-smooth muscle actin overexpression. Subsequently, these activated myofibroblasts deposit dense bands of extracellular matrix and collagen fibers across the uterine cavity. Because these processes feed directly into one another, disrupting this vicious cycle requires a multifaceted molecular intervention rather than simple physical separation.

Current Therapeutic Barriers to Prevent Intrauterine Adhesions

Standard clinical protocols primarily utilize hysteroscopic adhesiolysis followed by the insertion of physical barriers, including intrauterine balloons, copper-free devices, or hyaluronic acid gels. Furthermore, clinicians routinely prescribe high-dose systemic estrogen therapy to stimulate residual endometrial regeneration. However, these conventional modalities demonstrate substantial recurrence rates ranging between thirty and sixty percent in moderate-to-severe cases. Passive barrier devices merely provide transient mechanical separation without mitigating the underlying inflammatory and oxidative milieu. In addition, high-dose exogenous hormones carry thromboembolic risks and frequently fail when basalis stromal progenitors are depleted. Most importantly, none of the traditional therapies can simultaneously scavenge reactive radicals, suppress TGF-β1 signaling, and encourage angiogenesis. Consequently, advanced bioengineered platforms capable of smart drug delivery have become indispensable to prevent intrauterine adhesions permanently.

Engineering the Injectable ROS-Responsive CeTA@GPP Hydrogel

To address these critical therapeutic gaps, investigators developed an intelligent composite hydrogel system termed CeTA@GPP. Specifically, researchers synthesized cerium-tannic acid metal-phenolic nanozymes (CeTA) that exhibit potent superoxide dismutase-like and catalase-mimetic enzymatic activities. They encapsulated these nanozymes within a dynamic gelatin-based hydrogel crosslinked via boronate ester bonds. Under normal physiological conditions, the boronate ester network remains remarkably stable, allowing minimally invasive intrauterine catheter injection and conformal luminal coverage. Conversely, when the hydrogel encounters elevated reactive oxygen species within the injured uterine microenvironment, the boronate bonds undergo selective cleavage. As a result, the hydrogel degrades on demand, delivering therapeutic CeTA nanozymes directly into the inflammatory niche. This smart responsiveness guarantees sustained local bioactivity while eliminating premature drug clearance.

Cellular Mechanisms and Microenvironment Reprogramming

Extensive in vitro evaluations demonstrate that the CeTA@GPP hydrogel fundamentally reprograms damaged cellular pathways. By rapidly eliminating excess superoxide anions and hydrogen peroxide, the CeTA nanozymes normalize intracellular redox status and restore collapsed mitochondrial membrane potentials. Moreover, this substantial reduction in oxidative stress alters immune signaling, successfully shifting pro-inflammatory M1 macrophages toward the pro-healing, reparative M2 phenotype. Consequently, the anti-inflammatory microenvironment downregulates master pro-fibrotic drivers, particularly TGF-β1 and connective tissue growth factor. In human endometrial stromal cells, treatment robustly attenuates myofibroblast differentiation and curtails excessive collagen secretion. Thus, the hydrogel orchestrates a synchronized transition from sustained inflammatory destruction toward active tissue healing and matrix remodeling.

In Vivo Endometrial Regeneration and Functional Recovery

In preclinical rat models of traumatic intrauterine adhesion, in situ administration of CeTA@GPP hydrogel produced remarkable functional recovery. Transcriptomic analyses confirmed coordinated downregulation of pro-inflammatory cascades, oxidative stress responses, and fibrotic signaling pathways. Histologically, treated uterine horns exhibited restored endometrial thickness, renewed luminal epithelial architecture, and increased glandular density. Furthermore, the hydrogel stimulated robust microvascular angiogenesis, which provided essential nutrient delivery for regenerating stroma. Crucially, functional pregnancy assessments revealed marked improvements in blastocyst implantation rates and fetal development compared to untreated controls. By integrating mechanical barrier separation with responsive catalytic bioactivity, this cutting-edge platform re-establishes a receptive uterine cavity, offering a robust clinical horizon for female fertility preservation.

Frequently Asked Questions

How does the ROS-responsive hydrogel differ from standard physical barriers?

Conventional physical barriers only separate uterine walls mechanically, leaving underlying oxidative stress and inflammation unchecked. In contrast, the ROS-responsive hydrogel senses elevated reactive oxygen species at the injury site. Consequently, it degrades selectively to release catalytic nanozymes on demand. This dual mechanism prevents mechanical synechiae while simultaneously neutralizing toxic radicals and reversing fibrosis.

What enzymatic activities do cerium-tannic acid nanozymes demonstrate?

Cerium-tannic acid nanozymes exhibit robust superoxide dismutase-mimetic and catalase-mimetic catalytic activities. Specifically, they rapidly convert cytotoxic superoxide anions into oxygen and hydrogen peroxide, and subsequently degrade hydrogen peroxide into harmless water. By continuously scavenging these reactive oxygen species, the nanozymes relieve intracellular oxidative stress, protect mitochondrial integrity, and preserve endometrial stromal viability.

Why is macrophage repolarization crucial for endometrial repair?

Persistent pro-inflammatory M1 macrophages secrete high levels of TGF-β1, driving abnormal myofibroblast differentiation and extensive collagen deposition. Promoting repolarization into the anti-inflammatory M2 phenotype shuts down this fibrotic signaling cascade. Furthermore, M2 macrophages secrete pro-angiogenic factors and regenerative molecules that facilitate rapid glandular re-epithelialization and restore functional uterine receptivity.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. Refer to the latest local and national guidelines for clinical practice.

References

Cheng P et al. An Injectable ROS-Responsive Nanozyme Hydrogel Regulates the Uterine Microenvironment to Prevent Intrauterine Adhesions. Adv Sci (Weinh). 2026 Aug 30. doi: 10.1002/advs.77510. PMID: 42669616.

Zhao Y, Tan D, Weng Y, Gao JQ. Hydrogel-Based Systems in Intrauterine Adhesions: Bridging the Gap from Bench to Bedside. Bioact Mater. 2026;32:112-128.

Liu F, Zhu Z, et al. Unveiling the Pathological Landscape of Intrauterine Adhesion: Mechanistic Insights and Biomaterial Innovations. Front Bioeng Biotechnol. 2025;13:1264006.